Market Overview

Shire To Acquire NPS Pharmaceuticals for $5.2 Billion

Share:
Shire To Acquire NPS Pharmaceuticals for $5.2 Billion
Related NPSP
3 Niche ETFs Breaking Out
Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results
Related
Earnings Scheduled For February 16, 2017
KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'
The Risks Keep Rising For Roche's Hemophilia Hope (Seeking Alpha)

Shire PLC (NASDAQ: SHPG) has agreed to acquire NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) for $5.2 billion or $46 a share. Shire wanted to add more rare disease drugs to their portfolio.

This is a 38 percent premium to the average price of NPS stock over the last 45 days and about a 10 percent premium to Friday's close ($41.91).

This acquisition comes after many rumors that Shire was interested.

In June 2014, shares of NPS spiked on a report that Shire was interested in buying the company. NPS stated that it hadn't had any talks with Shire. Rumors heated up once again last month.

On January 5, the Wall Street Journal reported that NPS hired Goldman Sachs to gauge if other companies were interested in an acquisition.

The acquisition comes ahead of NPS' PDUFA decision for Natpara on January 24.

Both companies are scheduled to present at the JP Morgan Healthcare Conference this week.

This acquisition comes after the AbbVie Inc (NYSE: ABBV) and Shire acquisition talks fell through last year. As part of the breakup, Shire received $1.6 billion.

Many analysts think that Shire may be looking to acquire more companies this year.

Posted-In: News Wall Street Journal FDA M&A Best of Benzinga

 

Related Articles (NPSP + ABBV)

View Comments and Join the Discussion!